SPX-101, designed to help clear mucus from the lungs of people with cystic fibrosis, has the potential to treat all CF patients — regardless of disease-causing mutations. The experimental peptide, which blocks the overactive sodium channels that line CF lung cells so more fluids are retained on airway surfaces to hydrate mucus, was developed by Spyryx Biosciences. Isabelle […]
The post #ECFS2018 – Phase 2 Trial Supporting SPX-101 as Treatment for All with CF, Spyryx CMO Says appeared first on Cystic Fibrosis News Today. |
No hay comentarios:
Publicar un comentario